格隆汇8月18日丨药明康德(02359.HK)发布公告，2025年8月18日耗资2999.76万元人民币回购30.79万股 A股，回购价格每股96.65-99.12元。 ...

药明康德（603259）(02359)发布公告，于2025年8月18日斥资2999.76万元回购A股股份30.79万股，每股 回购价格为96.65-99.12元。 ...

智通财经APP讯，药明康德(02359)发布公告，于2025年8月18日斥资2999.76万元回购A股股份30.79万 股，每股回购价格为96.65-99.12元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 第 1 頁 共 12 頁 v 1.3.0 | 1). | 購回股份(或其他證券)但沒有註銷 | 302,500 | 0.01 % | RMB | 66.14 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | | | | | | | 通函，及於2025年4月29日刊發的投票結果公告。 | | | | | | | 於2025年6月26日，本公司實施2025年以集中競價交易方式回購本公司 | | | | | | | A股股份方案（"2025年第一次回購"），并回購302,500股A股股份。 | | | | | | | 變動日期 2025年6月26日 | | | | | | 2). | 購回股份(或其他證券)但沒有註銷 | 303,367 | | | | | | | | 0.01 % | RMB | 65.96 | ...

Core Insights - The healthcare services sector experienced a rise of 1.26% on August 18, with a net outflow of 1.405 billion yuan in principal funds [1] - Among the constituent stocks, 33 increased in value while 9 decreased [1] Fund Flow Analysis - The top net outflows were recorded for WuXi AppTec at 478 million yuan, Innovent Biologics at 410 million yuan, and Kelun Pharmaceutical at 175 million yuan [1] - Other notable outflows included Sanbo Brain Science at 157 million yuan and Ruizhi Pharmaceutical at 54.73 million yuan [1] Stock Performance - Key stocks with significant performance included: - Kanglong Chemical with a price of 30.94 and an increase of 2.35%, attracting a net inflow of 68.68 million yuan [1] - Baihua Pharmaceutical at 8.78, up 10.03%, with a net inflow of 63.97 million yuan [1] - Aier Eye Hospital at 13.22, up 1.34%, with a net inflow of 784.89 thousand yuan [1] - Huakang Clean at 33.28, up 13.39%, with a net inflow of 3316.13 thousand yuan [1] - Tongce Medical at 46.18, up 2.26%, with a net inflow of 3071.04 thousand yuan [1]

Group 1 - The main focus of the article is on the significant outflow of capital from specific stocks as of August 18, with notable amounts listed for each company [1] - The top three companies with the highest capital outflow are: Wolong Electric Drive (-1.518 billion), Tianfeng Securities (-1.458 billion), and Dongfang Wealth (-1.100 billion) [1] - Other companies experiencing substantial outflows include: Quzhou Development (-603 million), Bank of China Securities (-519 million), and Industrial Fulian (-452 million) [1] Group 2 - The article provides a detailed list of the top 20 stocks with the largest capital outflows, indicating a trend of investor withdrawal from these companies [1] - The total outflow amounts for the listed companies range from 2.42 billion to 15.18 billion, highlighting a significant shift in investor sentiment [1] - The data reflects a broader market trend that may impact future investment strategies and stock performance [1]

Group 1 - The Hong Kong stock market experienced a rise and then a pullback, with the Hang Seng Index reaching a new high [1] - The National Healthcare Security Administration is publishing a list of drugs that have passed preliminary review for the "2025 National Medical Insurance Directory and Commercial Insurance Innovative Drug Directory," which will enter expert review and negotiation stages [1][2] - The Hong Kong Innovative Drug Selected ETF (520690) saw a nearly 2.5% increase, with a trading volume exceeding 20 million and a turnover rate over 5%, indicating strong market interest [1] Group 2 - The dual-track policy of basic medical insurance and commercial insurance for innovative drugs signals a payment closure model, suggesting that "true innovation is easier to scale" [2] - The performance of innovative drugs is expected to be positively impacted by the dual-track payment system and significant business development opportunities, leading to a systematic revaluation of the Chinese innovative drug sector [2] - The Hang Seng Medical ETF (513060) is benefiting from the dual advantages of technology penetration and market expansion, particularly in AI healthcare and innovative drug companies [3]

Group 1 - The stock price of WuXi AppTec closed at 97.80 yuan on August 15, 2025, down by 0.89% from the previous trading day [1] - The company operates in the medical services industry and is a global leader in pharmaceutical research and development services, covering drug discovery, development, and manufacturing services [1] - For the first half of 2025, WuXi AppTec reported revenue of 20.799 billion yuan and a net profit attributable to shareholders of 8.561 billion yuan [1] Group 2 - On August 15, WuXi AppTec repurchased 290,000 A-shares, with a total payment amount of 27.99 million yuan [1] - On the same day, the net outflow of main funds was 236 million yuan, while the cumulative net inflow of main funds over the past five trading days was 1.119 billion yuan [1]

Group 1 - The core index, the CESHKB, increased by 1.74% to 9852.81 points with a trading volume of 14.774 billion [1] - The CESHKB index has risen by 20.92% in the past month, 69.27% in the past three months, and 116.13% year-to-date [1] - The index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd. and aims to reflect the overall performance of biotechnology companies listed in Hong Kong [1] Group 2 - The top ten weighted stocks in the CESHKB index include: - CanSino Biologics (13.72%) - Innovent Biologics (9.48%) - 3SBio (8.99%) - WuXi Biologics (8.61%) - BeiGene (8.53%) - WuXi AppTec (6.93%) - Kintor Pharmaceutical (4.94%) - Zai Lab (4.28%) - Nuo Therapeutics (4.1%) - Genscript Biotech (3.78%) [1] - The CESHKB index is entirely composed of stocks listed on the Hong Kong Stock Exchange, with 100% allocation [2] - The index's holdings are exclusively in the healthcare sector, with 100% allocation to the pharmaceutical and healthcare industry [2]

Core Viewpoint - WuXi AppTec (603259)(02359) announced a share buyback plan, investing 27.99 million RMB to repurchase 285,500 A-shares at a price range of 96.71 to 99.28 RMB per share [1] Group 1 - The company plans to repurchase shares on August 15, 2025 [1] - The total investment for the buyback is 27.99 million RMB [1] - The number of shares to be repurchased is 285,500 [1]